← ANALYST RATINGS · TIPRANKS
Incyte (INCY): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy7 Hold0 Sell
Ratings of 15 analysts in the last 3 months · top analysts only12-month forecast
Based on 15 price targets given in the last 3 months, the average target is $132, the highest $157, the lowest $113. The average is +16.9% from the last price of $113.
Analyst ratings 24
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $114 | Hold | +0.8% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $128 → $130+1.6% | Buy | +15.0% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $128 → $130+1.6% | Buy | +15.0% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $129 → $131+1.6% | Buy | +15.9% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $129 → $131+1.6% | Buy | +15.9% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $132 → $134+1.5% | Buy | +18.5% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $131 → $133+1.5% | Buy | +17.6% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $152 | Buy | +34.4% | Reiterated | 15.10.26on TipRanks 07:30 | +1.2%next day +0.9% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $128 | Hold | +13.2% | Reiterated | 15.10.26on TipRanks 07:26 | +1.2%next day +0.9% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $105 → $115+9.5% | Hold | +1.7% | Reiterated | 14.10.26on TipRanks 08:30 | +3.8%next day +1.2% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $152 | Buy | +34.4% | Reiterated | 13.10.26on TipRanks 06:26 | −2.4%next day +3.8% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $139 | Buy | +22.9% | Reiterated | 13.10.26on TipRanks 04:50 | −2.4%next day +3.8% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $130 | Hold | +15.0% | Reiterated | 12.10.26on TipRanks Oct 13 01:00 | −1.2%next day −2.4% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $140 | Buy | +23.8% | Reiterated | 09.10.26on TipRanks 08:15 | −0.6%next day −1.2% · 5 days +2.2% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $145 → $157+8.3% | Buy | +38.9% | Reiterated | 05.10.26on TipRanks 06:45 | −1.7%next day −1.8% · 5 days −2.8% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $120 → $123+2.5% | Hold | +8.8% | Reiterated | 28.09.26on TipRanks 08:06 | +1.5%next day −1.1% · 5 days −9.8% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $104 | Hold | −8.0% | Reiterated | 25.09.26on TipRanks Sep 26 08:16 | −1.0%next day +1.5% · 5 days −6.7% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Hold | — | Reiterated | 19.08.26on TipRanks 14:45 | +3.8%next day −0.1% · 5 days +0.1% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $110 → $130+18.2% | Buy | +15.0% | Reiterated | 17.08.26on TipRanks 07:20 | +3.3%next day +0.7% · 5 days +4.8% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $121 → $137+13.2% | Buy | +21.2% | Reiterated | 03.08.26on TipRanks 11:30 | −2.3%next day 0.0% · 5 days +0.6% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $131 → $155+18.3% | Buy | +37.1% | Reiterated | 03.08.26on TipRanks 06:20 | −2.3%next day 0.0% · 5 days +0.6% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $110 → $118+7.3% | Hold | +4.4% | Reiterated | 29.07.26on TipRanks 09:09 | −0.6%next day −4.9% · 5 days −11.3% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $104 → $119+14.4% | Hold | +5.2% | Reiterated | 29.07.26on TipRanks 07:27 | −0.6%next day −4.9% · 5 days −11.3% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $136 → $150+10.3% | Buy | +32.7% | Reiterated | 28.07.26on TipRanks Jul 29 07:38 | +9.1%next day −0.6% · 5 days −11.3% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $113 | Hold | −0.1% | Reiterated | 28.07.26on TipRanks Jul 29 07:27 | +9.1%next day −0.6% · 5 days −11.3% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $107 → $120+12.1% | Buy | +6.1% | Reiterated | 28.07.26on TipRanks 13:50 | +9.1%next day −0.6% · 5 days −11.3% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | $124 → $138+11.3% | Buy | +22.0% | Reiterated | 28.07.26on TipRanks 08:30 | +9.1%next day −0.6% · 5 days −11.3% | ↗ |
| Unknown Analyst | Argus Research | $115 | Buy | +1.7% | Reiterated | 30.04.26on TipRanks May 4 07:55 | −4.9%next day +1.4% · 5 days +0.8% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $94.00 | Hold | −16.9% | Downgrade | 15.03.26on TipRanks Mar 16 05:25 | −0.5%next day +1.0% · 5 days −1.0% | ↗ |
| Unknown Analyst | Evercore ISI | $73.00 → $110+50.7% | Hold | −2.7% | Reiterated | 05.03.26on TipRanks Mar 7 01:06 | −1.0%next day −0.1% · 5 days −3.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Incyte
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $132 at a price of $121 (+8.5%); now: $132 at $113 (+16.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 26 | 34 | 34 | 33 | 17 | 12 |
| Hold | 12 | 18 | 26 | 27 | 20 | 13 |
| Sell | 3 | 4 | 3 | 2 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-3.58 (from $-4.46 to $1.93). Last quarter: $3.09.
Sales
Next quarter’s sales estimate — $1.5B (from $1.4B to $1.5B). Last quarter: $1.7B.
Best top-analyst consensus in the sector · Healthcare
About Incyte
- CEO: William J. Meury
- Employees: 2,844
- 1801 Augustine Cut-Off, Wilmington, DE, 19803, US
- www.incyte.com
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Data from the stock’s TipRanks forecast page, read 26 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗